BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22430969)

  • 1. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
    Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream isolates at a Taiwanese hospital: clinical impacts of lowered breakpoints for carbapenems.
    Lee NY; Wu JJ; Lin SH; Ko WC; Tsai LH; Yan JJ
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1941-50. PubMed ID: 22249422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
    Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
    Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMERGENCY ROOM: AN UNRECOGNIZED SOURCE OF EXTENDED-SPECTRUM β-LACTAMASE PRODUCING ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE.
    Pornsinchai P; Chongtrakool P; Diraphat P; Siripanichgon K; Malathum K
    Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):51-62. PubMed ID: 26513905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi.
    Taneja J; Mishra B; Thakur A; Dogra V; Loomba P
    J Infect Dev Ctries; 2010 Sep; 4(8):517-20. PubMed ID: 20818104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteremia Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-Year Study.
    Chang K; Rattanavong S; Mayxay M; Keoluangkhot V; Davong V; Vongsouvath M; Luangraj M; Simpson AJH; Newton PN; Dance DAB
    Am J Trop Med Hyg; 2020 May; 102(5):1137-1143. PubMed ID: 32157990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.